Skip to main content

Table 2 Clinical and laboratory features at MAHA diagnosis and association with 4-week survival

From: Characteristics and outcome of breast cancer-related microangiopathic haemolytic anaemia: a multicentre study

  

Univariate analysis

 

Multivariate analysis

 

Factors

N (%)

OR

95% IC

p value

OR

95% IC

p value

PS at MAHA diagnosis

 PS 1–2

30 (55.6%)

1.0

 

0.003

1.0

 

0.01

 PS 3–4

24 (44.4%)

6.0

[1.8; 19.8]

 

7.0

[1.6; 31.8]

 

Clinical bleeding

 Yes

9 (16.7%)

NS

  

NS

  

 No

45 (83.3%)

      

Neurological symptoms

 Yes

15 (28.3%)

NS

  

NS

  

 No

38 (71.7%)

      

 NA

1

      

Dyspnoea

 Yes

11 (20.8%)

NS

  

NS

  

 No

42 (79.2%)

      

 NA

1

      

Metastatic sites

 < 3

25 (46.3%)

NS

  

NS

  

 ≥ 3

29 (53.7%)

      

Metastasis

 Bone marrowa

11 (78.5%)

      

 Bone

44 (81.5%)

      

 Lung

8 (14.8%)

NS

  

NS

  

 Liver

35 (64.8%)

      

 Otherb

24 (44.4%)

      

Number of prior treatment lines

 ≤ 1

26 (48.1%)

1.0

 

0.06

NS

  

 > 1

28 (51.9%)

2.9

[1.0; 8.7]

    

Platelets

 < 50 G/L

29 (53.7%)

NS

  

NS

  

 ≥ 50 G/L

25 (46.3%)

      

Haemoglobin

 < 8 g/L

26 (48.1%)

4.0

[1.3; 12.5]

0.02

3.7

[0.9; 16.7]

0.08

 ≥ 8 g/L

28 (51.9%)

1.0

  

1.0

  

Schistocytes

 > 5.0%

10 (25.0%)

NS

  

NS

  

 0.5–5.0%

30 (75.0%)

      

 NA

14

      

Erythroblastemia

 Yes

40 (85.1%)

NS

  

NS

  

 No

7 (14.9%)

      

 NA

7

      

Myelemia

 Yes

38 (90.5%)

NS

  

NS

  

 No

4 (9.5%)

      

 NA

12

      

Prothrombin time

 < 50%

8 (16.0%)

4.5

[0.9; 25.0]

0.07

9.1

[1.2; 50.0]

0.03

 ≥ 50%

42 (84.0%)

1.0

  

1.0

  

 NA

4

      

Fibrinogen

 ≤ 2 g/L

15 (34.9)

NS

  

NS

  

 > 2 g/L

28 (65.1)

      

 NA

11

      

Glomerular filtration eate

 > 60 mL/min

25 (65.8%)

NS

  

NS

  

 30–60 mL/min

9 (23.7%)

NS

     

 < 30 mL/min

4 (10.5%)

NS

     

 NA

16

      

Total bilirubin level

 < 1.24 mg/dL

16 (30.8%)

1.0

 

0.007

1.0

  

 ≥ 1.24 mg/dL

36 (69.2%)

7.3

[1.8; 30.6]

 

6.9

[1.1; 42.6]

0.04

 NA

2

      

Pronopall scorec

 Short survival

12 (31.6%)

3.7

[0.8; 16.8]

0.09

   

 Intermediate/long survival

26 (68.4%)

1.0

  

NS

  

 NA

16

      
  1. NA not available, OR odds ratio, NS non-significant
  2. aOnly 14 patients had a bone marrow examination (myelogram or bone marrow biopsy) at the time of BC-MAHA diagnosis
  3. bOthers metastatic sites: cerebral, carcinomatous meningitis, node involvement
  4. cThe pronopall score for early death among oncology patients was calculated according to Barbot et al., J Clin Oncol 2008, missing data being imputed
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us